
UK MHRA Approves Blenrep Combos for Relapsed/Refractory Multiple Myeloma
UK MHRA Approves Blenrep Combos for Relapsed/Refractory Multiple Myeloma GSK plc has achieved a critical regulatory milestone with the Medicines and Healthcare products Regulatory Agency (MHRA) granting authorisation for expanded use of Blenrep (belantamab mafodotin-blmf) in the United Kingdom. This…